Promising
Thioctic acid: protect nerve tissue in secondary progressive MS
secondary progressive MS · Mitochondrial / oxidative stress
A controlled phase 2 trial was positive. Phase 2 trials are small and often measure early markers, so this is a signal, not proof.
- Trials
- 2
- Running now
- 1
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 54
How the verdict was reached
Positive in phase 2 only
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| Thioctic acid, phase 3 | Phase2|phase3 | 54 | 2010 | Met its main goal After 2 years, the annualized PCBV was significantly less in the LA arm compared with placebo (-0.21 [standard error of the coefficient estimate (SEE) 0.14] vs -0.65 [SEE 0.10], 95% confidence interval [CI] 0.157-0.727, p = 0.002). Paper abstract | Counted |
| OCTOPUS | Phase 3 | 1,200 | 2023 | Still running | Not counted: not randomised |
Counted: 1. Will count later: 0. Not counted: 1.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026Trials: 1 → 2
- Oct 2026Status changed from Confirmed to Promising
- Oct 2026Status changed from Results pending to Confirmed
- Oct 2026Status changed from Confirmed to Results pending
- Oct 2026First listed as Confirmed
Related hypotheses
- Acetylcysteine: protect nerve tissue in secondary progressive MS
- Metformin: protect nerve tissue in secondary progressive MS
- Thioctic acid: protect nerve tissue in optic neuritis
- Thioctic acid: protect nerve tissue in primary progressive MS
- Biotin: slow disability worsening in secondary progressive MS
- Metformin: slow disability worsening in secondary progressive MS
- Metformin: reduce relapses and new lesions in secondary progressive MS
Assembled by software from public sources.